Cytyc has appointed Marla Persky to its board of directors, and has announced the resignation of Anna Richo, who has served as a director since 1998.
Persky is the deputy general counsel of Baxter Healthcare, the principal domestic operating subsidiary of Baxter International, a position she has held since 2001. She has also been general counsel for Baxter’s Renal Business Group, and general manager of Althin Medical, an acquired business that she helped to run and integrate.
Before joining Baxter, Persky was an attorney with Lurie, Sklar & Simon, where she specialized in health-care litigation and product liability defense. She received her undergraduate degree from Northwestern University and her law degree from Washington University School of Law in St. Louis, Missouri. Richo left to join Amgen.
Applied DNA Sciences has hired Kyle Keogh to manage its newly established sales office located in Florida.
Keogh comes to Applied DNA Sciences from Smart Biometrics, a smart card and biometric technology company he co-founded in 1999. He also invented the BioVault, believed to be the first embedded biometric access control device. Smart Biometrics was sold in May to Sequiam Biometrics, a wholly owned subsidiary of Sequiam.
Robert Middlebrook has joined Perlegen Sciences as chief corporate development officer, a position created for Middlebook as the company expands its partnerships to in-license drug candidates.
Middlebrook joins Perlegen from Fidelity Investments, where he held numerous positions over the past 11 years, including, most recently, senior vice president. Before joining Fidelity, Middlebrook was vice president and principal at Regent Capital, and was at Alpha Industries, a defense electronics firm, for four years.
Alan Nies has been appointed to the board of directors of Lexicon Genetics.
Nies has served as chairman of the Woodlands, Texas-based company’s medical advisory board since March [see 3/28/03 SNPtech Reporter]. Most recently, he was senior vice president of clinical sciences at Merck. Before joining Merck, Nies was a professor of Medicine and head of the division of clinical pharmacology at the University of Colorado Health Sciences Center.
James Chamberlain has been appointed chairman of the board of directors at Marligen Biosciences, the Ijamsville, Md., company said today. Chamberlain, who currently serves on the board of Xtrana, a Denver biotechnology company, was president of BioSource International from 1989 to 1993, and chairman of the board from 1993 to 2000, when he retired. He has previously served as manager of business development at Amgen, and in executive roles at Amersham and Browning Ferris Industries.
Joe Fanelli has been appointed director of corporate development at Health Discovery, the company said last week. Fanelli comes to the company marketing sales and business development positions at Structural Bioinformatics, American Bionetics, Cangene, Microgenics, and Quantum Biotechnologies.